Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Alamar Biosciences announces the launch of the NULISAqpcr™ AD 5-plex assay, advancing blood-based biomarker detection for Alzheimer’s disease research

blood-based biomarkers relevant to the Alzheimer's Association recommended guidelines: brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and APOE4...

Ad Hoc Analyses Indicate Enhanced Survival Outcomes with VYLOY™ (zolbetuximab) Combined with Chemotherapy When Common Adverse Events Are Properly Managed

from the combined Phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies in patients with HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction. (GEJ) adenocarcinoma in ESMO Open, characterizing the management of...

PureWay and PPSWG Form New Partnership to Transform Pharmaceutical Waste Management in the U.S.

waste management. Millions of Americans rely on self-administered injectable medications every day, including insulin, GLP-1 therapies, migraine biologics, and autoimmune biologics. The resulting waste (billions of discarded needles and syringes)...

Clover Begins Phase 2 Clinical Evaluation of a Combination Respiratory Vaccine Targeting RSV, hMPV, and ± PIV3

that enrollment of the first participants has been completed in a Phase 2 clinical trial in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) protein-based vaccine candidates based on prefusion-stabilized F (PreF)-Trimer...

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

for Reconstitution, for fibrinogen replacement in patients with acquired fibrinogen deficiency (AFD). This new kit includes 100 mL of Water for Infusion (WFI) and continues to feature the nextaro® reconstitution device, offering enhanced...

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

tract, supporting sustained therapeutic exposure throughout the day. Aizhida was approved by the U.S. FDA in March 2021 as a once-daily treatment option for patients with ADHD 6 years of age and older. ADHD is a common, chronic neurodevelopmental...

Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

brings nearly three decades of experience in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on 1 January 2026. Reflecting Novotech’s increasingly international profile, Dr. Tharmaratnam will...

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Measures MOCA (Montreal Cognitive Assessment) scores remained unchanged at week 22, compared to baseline (Baseline, 13.5 and week 22, 14) suggesting no decline in cognitive function over the 22-week period. CDR-FTLD scores did not significantly...

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

diseases, announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service...

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's...

In Europe, Samsung Bioepis begins the commercialization of BYOOVIZ®, a biosimilar to Lucentis (Ranibizumab)

Bioepis Co., Ltd. announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to...

Peer-reviewed validation of a 60-channel closed-loop neurostimulation brain implant is published by Nia Therapeutics

neuromodulation. Systematic variation of stimulation parameters produced dose-dependent changes in alpha-band (8–12 Hz) and gamma-band (78–82 Hz) neural activity, confirming that stimulation reliably modulates physiological signals....

Matisse Pharmaceuticals receives INN for M6229, recognizing it as a first-in-class drug, isupartob sodium

Marcel Jacobs, CEO of Matisse Pharmaceuticals. About Matisse Pharmaceuticals Matisse Pharmaceuticals B.V. was founded in 2014 in Geleen, the Netherlands. Matisse is dedicated to develop a product portfolio of safe and innovative therapies for...

Sapio Sciences Collaborates with the Wellcome Sanger Institute on Transforming Digital Laboratories

Sapio Sciences, the science-awareTM AI lab informatics platform, announced that the Wellcome Sanger Institute has selected the Sapio Informatics Platform as its central LIMS to underpin the Institute’s ambitious lab transformation program. The...

Medra Raises $52 Million in Series A Funding to Build Physical AI Scientists

machine learning or AI-driven software without any robotic execution. Bringing a new medicine to market still takes 10-15 years and over $2B because discovery and preclinical work are slow, manual, and fragmented. Pharma has tried to fix this with...

Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards

for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation in adult and adolescent patients aged 12 years and older and...

FIZE Medical, in an exclusive deal with Asahi Kasei Medical, has launched the FIZE kUO® System in Japan

FIZE Medical Inc., a leader in smart fluid management solutions for critically ill patients, announced an exclusive distribution agreement with Asahi Kasei Medical Co., Ltd. to launch the FIZE kUO® system in Japan. Asahi Kasei Medical, a world...

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

webinar "Advancing bariatric endoscopy" Join Prof. Ivo Boskoski, MD, Christopher McGowan, MD and Abdullah AlMousa, MD on 11 December for a live online session on the latest developments in bariatric endoscopy and GMA with MOVIVA®: Webinar...

Within one year of its launch, L&C Bio's 'Re2O' has emerged as a leading procedure in K-Medical Tourism

This growth is particularly remarkable considering that Re2O had relatively low brand recognition only six months ago. Dermatology and plastic surgery clinics, as well as major university hospitals across Korea, have recently accelerated adoption...

Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

Celltrion, Inc. announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea. “Today’s approval lays a...